This tag is associated with 5 posts

Is a Mexican NICE on the Cards?

Whilst in the midst of researching for a report on HTA in Latin America (and determined to improve my understanding of Spanish), I found myself listening to a webinar on the Mexican Ministry of Health (MoH)’s National Centre for Health Technology Excellence (CENETEC). Despite the webinar’s sound quality and my poor Spanish, I learnt that … Continue reading

Trade envoy galvanises UK firms to invest in Brazilian healthcare

After a swift passage through the security check-point, that included an airport style search, I was officially inside the UK House of Commons on 25th January. Not only was this my first visit to the House of Commons, but also the first time a Brazilian Health and Life Sciences Seminar has taken place in the … Continue reading

A Latin Angle to Analysing Healthcare Systems

I wished I had practiced French beyond my school days was among my first thoughts when I attended the XXII congress of the Latin Association of Health Systems (ALASS) from 9 to 11 September in Lisbon, Portugal. A significant portion of the conference was dedicated to themed sessions, which had no simultaneous translation since the … Continue reading

Bye Bye CITEC, Hello CONITEC — Brazil’s New HTA Agency Aims for Stricter Reimbursement Requirements

Whilst conducting research on the Brazilian market for our latest multi-client study: The New REAlity of Relative Effectiveness — International Comparison of Evolving Requirements, I looked in detail at the major reform that has led to the newly formed HTA body, CONITEC. CONITEC stands for the National Commission for Incorporation of Technologies in the Unified … Continue reading

Drug Prices in Brazil, Russia and Turkey – A Comparison of Trends in Three Emerging Pharmaceutical Markets

In my work developing and analysing our database of global drug prices, I frequently come across interesting pricing trends – particularly in the current economic climate. Recently, I looked into drug prices and trends in three emerging countries: Brazil, Russia and Turkey. While pharmaceutical market values in developed countries are slowing down, an opposite trend … Continue reading

Enter your email address to follow this blog and receive notifications of new posts by email.

Download extract from IHS Flexible Pricing strategies multi client study
Drug Price Erosion Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global life sciences industry. Join us as we look at issues in healthcare policy, market access, pricing and reimbursement and R&D. Comments are welcome!
40 countries covered. Download a sample chapter on Brazil
Download a complimentary white paper on market-access risk ratings
Download a sample of the primary research and analysis on French P&R reform

Follow IHS Life Sciences on Twitter


Get every new post delivered to your Inbox.

Join 346 other followers